136 completed. 136 Phase 1, 35 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 136 | Completed 136 |
| Phase 2 | 35 | Completed 35 |
Follow Dyssomnias: new trials by email Literature Review of Dyssomnias trials Research Report on Dyssomnias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reliability of Standardized IQ Testing Under Modafinil, Racetam-Class Compounds, Sleep Restriction and Daily Activity Modafinil, Oxiracetam, Pramiracetam - Healthy, Cognition | Phase 1 | Completed | Abdulraheem Mohamed Gouda | 70 | 2026-03-09 | 2026-10-01 |
| A Study of HBS-201 (Pitolisant Delayed-release) HBS-201 - Narcolepsy | Phase 1 | Completed | Harmony Biosciences Management, Inc. | 46 | 2025-05-21 | 2025-12-12 |
| Impact of Nutritional Supplementation on Sleep Quality Sleep Supplements, Placebo - Sleep, Sleep Quality | Phase 1 | Completed | Pharmavite LLC | 376 | 2025-05-15 | 2026-02-27 |
| A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets YZJ-1139 tablets, Escitalopram oxalate tablets, YZJ-1139 simulated tablets - Insomnia, Central Nervous System | Phase 1 | Completed | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 24 | 2024-08-31 | 2026-06-30 |
| A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects YZJ-1139 tablets, Ticagrelor Tablets - Insomnia | Phase 1 | Completed | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 27 | 2024-08-22 | 2026-06-30 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1 E2086, E2086 Placebo, Active Comparator - Narcolepsy Type 1 (NT1) | Phase 1 | Completed | Eisai Inc. | 22 | 2024-06-20 | 2025-06-04 |
| Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment YZJ-1139 - Insomnia, Renal Impairment | Phase 1 | Completed | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 16 | 2024-06-03 | 2026-06-30 |
| Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment YZJ-1139 - Insomnia, Hepatic Impairment | Phase 1 | Completed | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 24 | 2024-03-22 | 2024-11-04 |
| A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003) MK-6552, MK-6552 placebo, Modafinil - Healthy, Narcolepsy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2024-03-19 | 2024-10-01 |
| The Efficacy and Safty of FMT in Patients With CID fecal microbiota, Placebo, synbiotics - Insomnia Chronic, Fecal Microbiota Transplantation | Phase 1 / Phase 2 | Completed | Peking University Sixth Hospital | 80 | 2023-10-08 | 2026-02-27 |
| Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC) transauricular Vagus Nerve Stimulation - Breast Cancer, Insomnia | Phase 1 | Completed | University of Alabama at Birmingham | 20 | 2023-09-26 | 2026-06-18 |
| A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005) MK-6552, Modafinil - Healthy, Narcolepsy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 12 | 2023-09-20 | 2024-10-30 |
| Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs IHL42X, Acetazolamide 250 MG, Dronabinol 2.5 MG - Obstructive Sleep Apnea | Phase 1 | Completed | Incannex Healthcare Ltd | 125 | 2023-09-08 | 2025-01-17 |
| Montmorency Cherry Supplementation, Sleep, and Inflammation Montmorency cherry supplement, Control - Insomnia Chronic, Inflammation | Phase 1 / Phase 2 | Completed | Michigan State University | 34 | 2023-02-18 | 2025-09-08 |
| Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1, Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2, Placebo Day 1 - OSA | Phase 1 / Phase 2 | Completed | Chulalongkorn University | 10 | 2023-02-01 | 2025-09-17 |
| Acetazolamide on REM OSA Placebo oral capsule, Acetazolamide - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 11 | 2023-01-30 | 2026-01-20 |
| Mirtazapine for Chronic Insomnia in Older Adults Mirtazapine 7.5 MG Oral Tablet once daily at bedtime, Placebo oral tablet once daily at bedtime - Chronic Insomnia | Phase 1 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 60 | 2022-10-01 | 2024-08-12 |
| BAY2586116 Nasal Spray and OSA Severity BAY2586116, Placebo - Sleep Apnea, Obstructive | Phase 1 | Completed | Flinders University | 10 | 2022-08-31 | 2023-02-15 |
| Cannabinol Use in Patients With Insomnia Disorder 30 mg Cannabinol (CBN), 300 mg Cannabinol (CBN), Placebo - Insomnia Disorder | Phase 1 / Phase 2 | Completed | Woolcock Institute of Medical Research | 20 | 2022-08-24 | 2024-02-06 |
| Feasibility Study of Personalized Trials to Improve Sleep Quality Melatonin 3 mg, Melatonin 0.5 mg, Cellulose placebo pill - Sleep Disturbance | Phase 1 | Completed | Northwell Health | 60 | 2022-05-11 | 2024-08-22 |
Showing 20 of 136. Sign in to see all of them.
Sleep Initiation and Maintenance Disorders (64) · Sleep Apnea, Obstructive (30) · Sleep Apnea Syndromes (16) · Narcolepsy (13) · Restless Legs Syndrome (8) · Sleep Deprivation (8) · Disorders of Excessive Somnolence (6) · Depression (5) · Parasomnias (5) · Sleep Wake Disorders (5) · Sleep Disorders, Circadian Rhythm (4) · Anxiety Disorders (3) · Apnea (2) · Attention Deficit Disorder with Hyperactivity (2) · Depressive Disorder, Major (2)
Nervous System Diseases (135) · Sleep Wake Disorders (131) · Sleep Disorders, Intrinsic (127) · Mental Disorders (98) · Respiratory Tract Diseases (42) · Respiration Disorders (40) · Apnea (38) · Sleep Apnea Syndromes (24) · Pathological Conditions, Signs and Symptoms (23) · Signs and Symptoms (18) · Neurologic Manifestations (12) · Disorders of Excessive Somnolence (11) · Behavior (8) · Parasomnias (8)
Zolpidem (8) · Modafinil (7) · lemborexant (6) · suvorexant (6) · N-((1-((5-(4-fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide (4) · TAK-925 (4) · zopiclone (4) · Mirtazapine (3) · 1-(((alpha-isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexaneacetic acid (2) · Acetazolamide (2) · Atomoxetine Hydrochloride (2) · Cognitive Behavioral Therapy (2) · Dietary Fiber (2) · Eszopiclone (2) · Flumazenil (2)
Merck Sharp & Dohme LLC (11) · Eisai Inc. (8) · Brigham and Women's Hospital (7) · GlaxoSmithKline (7) · Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (6) · Eli Lilly and Company (3) · Takeda (3) · XenoPort, Inc. (3) · Idorsia Pharmaceuticals Ltd. (2) · Janssen Research & Development, LLC (2) · Mayo Clinic (2) · Millennium Pharmaceuticals, Inc. (2) · Sunshine Lake Pharma Co., Ltd. (2) · University of California, San Francisco (2) · University of Utah (2)
United States (76) · China (10) · United Kingdom (9) · Canada (6) · Germany (6) · Netherlands (6) · Australia (5) · Japan (5) · Belgium (4) · France (4) · Israel (3) · Finland (2) · Italy (2) · Austria (1) · Czechia (1)
Gavin West, M.D. (2) · Alexandra Evancho, DPT (1) · Amy M Sawyer, PhD (1) · Andrew Krystal, M.D. (1) · Annemiek Vermeeren, PhD (1) · Aziz Laurent (1) · Barry F Chaitin, M.D. (1) · Beth A Malow, MD, MS (1) · Bradley A Edwards, PhD (1) · Brendon Yee, MBChB, FRACP, FCCP, PhD (1)
PMID 40848323, PMID 18056558, PMID 19581560, PMID 21632834, PMID 21856678, PMID 21966064, PMID 22131599, PMID 22237311, PMID 22302299, PMID 22549286, PMID 22572632, PMID 22893765, PMID 24122944, PMID 24290737, PMID 24587571, PMID 24815497, PMID 25467190, PMID 25661282, PMID 25805361, PMID 26194728, PMID 26240742, PMID 27092703, PMID 29246264, PMID 30395486, PMID 31419329, PMID 31642731, PMID 32215834, PMID 32511726, PMID 33057694, PMID 33305817, PMID 33491327, PMID 35306405, PMID 35748777, PMID 36805833, PMID 36883238, PMID 37193566, PMID 37209427, PMID 37256193, PMID 37535419, PMID 37612115, PMID 37677076, PMID 38286618, PMID 39069967, PMID 39266012, PMID 39502777, PMID 39688178, PMID 40088388, PMID 40135470, PMID 40135690, PMID 40668551
2018 (2), 2005 (1), R00NR011173 (1), R01HL065176 (1), R01LM012836 (1), R01NR004340 (1), R03MH062327 (1), R21NR009080 (1), R21NR010539 (1), R34MH070805 (1), R43NR010688 (1), UL1RR026314 (1)